Suzhou Xuanjing Biotechnology

Suzhou Xuanjing Biotechnology, operating as Rigerna, is a clinical-stage biopharmaceutical firm established in 2022, specializing in the development of small interfering RNA (siRNA) therapeutics. The company was founded by Dr. Yuanyu Huang, a distinguished scientist with more than 16 years of academic and industrial experience in the oligonucleotide field. His expertise is underscored by his ranking in the top 0.26% of the “Most Influential Scientists Globally” list, which provides a strong scientific foundation for the company's pursuits. The name 'Rigerna' is a blend of 'Rigel', one of the brightest stars, and 'RNA', reflecting the company's ambition to make significant achievements in the RNAi field.

Rigerna's strategic focus is on addressing unmet medical needs in kidney diseases. The company's business model centers on creating a pipeline of proprietary drug assets by leveraging its in-house technology platforms. These assets are then advanced through clinical development, with the potential for future licensing or commercialization partnerships. The company has secured over $30 million in initial seed and angel financing to support its research and development activities. Its operations are based in Suzhou and Beijing, China.

The core of Rigerna's operations lies in its three proprietary technology platforms: a nucleic acid sequence design and screening platform, a chemical modification platform, and an in-vivo delivery platform. This integrated approach underpins the development of its product pipeline, led by RG002, an siRNA therapeutic candidate for treating IgA nephropathy (IgAN). RG002, which is currently in Phase 1 clinical trials, has shown promise by reducing a key biomarker for IgAN by approximately 60% in non-human primate models. A key differentiator for the company is its novel kidney-targeting delivery platform, which has successfully completed proof-of-concept experiments in non-human primates, demonstrating efficient and targeted delivery of siRNA to the kidneys.

Keywords: siRNA therapeutics, drug discovery, biotechnology, kidney diseases, IgA nephropathy, oligonucleotide therapies, clinical-stage, RNAi, drug delivery platform, nucleic acid pharmaceuticals, biopharmaceutical, Yuanyu Huang, RG002, nephrology, genetic medicine, targeted therapy, life sciences, molecular medicine, preclinical development, venture capital